CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder

Here we report 3 cases of neuromyelitis optica spectrum disorder (NMOSD), who were all treated with eculizumab and could be observed with monitoring serum C3, C4 and 50% hemolytic complement (CH50) before and after the treatment. Serum C3 and C4 were not dramatically changed during the treatment, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Namatame, Chihiro, Misu, Tatsuro, Takai, Yoshiki, Nishiyama, Shuhei, Nakashima, Ichiro, Fujihara, Kazuo, Aoki, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809378/
https://www.ncbi.nlm.nih.gov/pubmed/33490671
http://dx.doi.org/10.1016/j.heliyon.2021.e05899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809378/
https://www.ncbi.nlm.nih.gov/pubmed/33490671
http://dx.doi.org/10.1016/j.heliyon.2021.e05899

Ejemplares similares